# Facilitate by-stander effects by EV-mRNA cargo in AAV gene therapy for MPS IIIC

> **NIH NIH R21** · UNIV OF NORTH CAROLINA CHAPEL HILL · 2020 · $427,625

## Abstract

Project Summary
MPS IIIC is a devastating lysosomal storage disease (LSD), for which there is no definitive treatment. To address
this unmet need, this proposed project is to develop a novel effective gene therapy product for treating MPS IIIC
using AAV vector to target the root cause. Notably, the neuropathologies in MPS IIIC are global, involving the
entire nervous system, and HGSNAT is a trans-lysosomal-membrane protein, which, unlike the majority of
lysosomal enzymes, cannot be secreted and taken-up by neighboring cells. Therefore, optimal therapeutic
benefits requires targeting as many cells as possible, which can be achieved by high-dose vector delivery, such
as recently approved Zolgensma for SMA.25 In comparison, studies have demonstrated that gene therapy for
MPS disorders involving a secretable protein required significantly lower vector doses. The high vector doses
has been a major challenge in translation of AAV gene therapy due to the scale-up capacity of vector production
for human application. All cells are known to continuously release extracellular vesicles (EVs) and communicate
by exchanging large molecules via EV traffic. The demonstrated properties of EV intercellular interaction offer a
potential tool to ease this challenge to translation of rAAV gene therapy. We hypothesize that incorporation of
EV-mRNA packaging signals in gene therapy vectors will engender by-stander effects for normally non-secreted
protein via the mRNA-containing EVs. To test this hypothesis, we will construct rAAV vectors that express
hHGSNAT and contain different putative EV packaging signals, and identify effective signals for EV-mRNA
loading. The goal is to develop an effective rAAV-hHGSNAT gene delivery approach for treating MPS IIIC. Data
generated may also provide powerful tools for developing gene therapy to treat other diseases involving non-
secreted transgene products. We believe this project is ideally suited to the R21 high risk/high impact funding
mechanism.

## Key facts

- **NIH application ID:** 10040153
- **Project number:** 1R21NS118165-01
- **Recipient organization:** UNIV OF NORTH CAROLINA CHAPEL HILL
- **Principal Investigator:** HAIYAN FU
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $427,625
- **Award type:** 1
- **Project period:** 2020-09-01 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10040153

## Citation

> US National Institutes of Health, RePORTER application 10040153, Facilitate by-stander effects by EV-mRNA cargo in AAV gene therapy for MPS IIIC (1R21NS118165-01). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10040153. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*